INTRODUCTION
============

Tuberculosis (TB) continues to exhibit the highest rate of morbidity and mortality among chronic infections worldwide ([@b10-jer-12-4-333]; [@b21-jer-12-4-333]). Each year, 8.9 million of new cases and 1.6 million of deaths are registered ([@b26-jer-12-4-333]). The prevalence of TB in developing countries remains high ([@b20-jer-12-4-333]). Cameroon recently reported a total of 26,110 cases of TB nationally, with 15,080 new smear-positive cases, corresponding to rates of 124 and 73 per 100,000 populations respectively ([@b2-jer-12-4-333]).

TB causes poor ventilation and gas exchange and an overall decline in functional status ([@b24-jer-12-4-333]). Furthermore, respiratory diseases as TB results in physical deconditioning, muscle atrophy and, impaired lung function and gas exchange ([@b7-jer-12-4-333]). The consequences of changes observed in muscle system are lower exercise tolerance, decrease in daily physical activities and impaired quality of life ([@b7-jer-12-4-333]; [@b15-jer-12-4-333]).

TB remains a global public health problem despite the presence of effective TB pharmacotherapy for more than 50 yr and the use of vaccines for more than 90 yr ([@b14-jer-12-4-333]). Nowadays, TB treatment is done in two phases: an initial intensive phase of two months comprising an association of Ethambutol (E), Isoniazid (H), Rifampicin (R) and Pyrazinamide (Z) (2HRZE), and a continuous phase of four months duration constituted of R and H (4RH) ([@b27-jer-12-4-333]).

The health recovery follow-up of TB patients is based, either on clinic, radiographic and laboratory examinations, (which often are more expensive for poor populations) or, on subjective declarations with respect to an eventual improvement of their physical capacities. Although, the ability to ambulate for a distance is a quick and inexpensive measure of physical function and an important component of quality of life since it reflects the capacity for undertaking daily activities ([@b24-jer-12-4-333]).

In general, functional walk tests are typically administered as a mean of evaluating functional status, monitoring effectiveness of treatment and establishing prognosis ([@b24-jer-12-4-333]). The 6-min walk test (6MWT) is widely used in evaluation of exercise capacities in respiratory diseases ([@b9-jer-12-4-333]) and other lung diseases ([@b25-jer-12-4-333]). 6MWT gives more advantages because practical and simple, low cost, reproducible and convenient for a group of many patients and only requires ability to walk. 6MWT is a submaximal test used as clinical indicator of the functional capacity in patients of cardiopulmonary diseases ([@b3-jer-12-4-333]). This test reflects better the daily life activities than laboratory tests, it is well tolerated by patients ([@b16-jer-12-4-333]; [@b17-jer-12-4-333]), and can also be used to evaluate the effects of a treatment administrated. The distance completed by a patient on a flat surface in 6-min walk may be used as a generic one-time measure of functional status or as an outcome measure from a rehabilitation program.

Many studies conducted using pulmonary rehabilitation have shown their efficacy in TB and post-TB patients ([@b4-jer-12-4-333]; [@b7-jer-12-4-333]; [@b8-jer-12-4-333]; [@b29-jer-12-4-333]). Because of high risk of contamination, little attention has been given to the effects of pulmonary TB in terms of physical disability, whereas physical performances of these patients could provide information on the disease gravity and administered treatment efficacy.

The present study has double objective: (a) To compare the baseline physical characteristics of TB patients with those of age-matched group of healthy people and, (b) to evaluate functional capacities of Cameroonian TB patients in initial intensive phase of treatment using the 6MWT.

MATERIALS AND METHODS
=====================

Participants
------------

The study was conducted in the Jamot Hospital of Yaounde (Cameroon). Twenty-eight new diagnosed patients of smear-positive pulmonary tuberculosis (TB+) of both sexes, who have signed a consent form to participate to the study were recruited. Patients were included if they were able to walk, with a respiratory rate \>30 cycles per minute, a Karnofsky index (IK)\>70 and in- or out-patients. All TB patients started taking medications for the treatment of TB. Nineteen healthy age-matched people from the normal population were chosen as a control for comparison. This longitudinal study was approved by the scientific committee of the hospital. The study was conducted in accordance with the Helsinki Declaration as revised in 1989.

Study design
------------

General, cardiovascular and pulmonary evaluations as well as the 6MWT were realized at diagnosis and after 2 months by the investigator and an experimented nurse.

General evaluation
------------------

After diagnosis confirmation by a medical doctor, weight, muscle mass (MM) and bone mass (BM) were recorded using a bio-impedance meter scale Tanita BC-532 (Tanita Corp., Tokyo, Japon). The IK was determined by a scale proposed by [@b13-jer-12-4-333]. The body mass index (BMI) was calculated by dividing the weight in kilogram by the square of the height in meter.

Oxygen saturation and Cardiovascular evaluation
-----------------------------------------------

Oxygen saturation (SpO~2~) and resting heart rate (HR) were measured with an electronic pulse oximeter (ChoiceMMed, OxyWatchC20, Beijing, China). Systolic blood pressure (SBP) and diastolic (DBP) were determined using an electronic blood pressure device (Medisana AG, Neuss, Germany).

Pulmonary evaluation
--------------------

This evaluation followed the American Thoracic Society/European Respiratory Society recommendations ([@b18-jer-12-4-333]). Forced expiratory volumes in 1 second (FEV~1~) and 6 seconds (FEV~6~), and the ratio FEV~1~/FEV~6~ were determined with an electronic peak-flow meter (Piko 6; nSpire Health Inc., Longmont, CO, USA). For each participant, two maneuvers of forced expiratory were realized after a maximal inspiration and the best value was recorded.

6-min walk test
---------------

The test was performed according to the American Thoracic Society guidelines ([@b5-jer-12-4-333]) in a 40-m-long straight hospital corridor, with line-marks every meter. Participants were instructed about the purpose of the test which was to see how far they could walk in 6 min. Participants were instructed to walk from one end to the other, covering as much ground as possible during the allotted time. No verbal encouragement was given during the test only the remaining duration was indicated every minute. The test was self-paced and participant could rest if they so wished. They were allowed to stop, if symptoms of significant distress like chest pain, dizziness or leg cramps occurred. However, they were asked to resume walking as soon as possible if they could. The distance covered was registered at 2, 4, and 6 min. At the end of the 6 min, cardiovascular and pulmonary parameters were again measured. The 6-min walk distance (6MWD) was recorded and the Borg score (rating of perceived exertion, RPE) determined using the modified Borg visual analog scale ([@b6-jer-12-4-333]).

The 6MWD was converted in 6-min walk work (6MWW) by multiplying the body weight in kilogram by 6MWD in meter (kg/m). The mean peak of oxygen consumption (VO~2\ peak~) was calculated using the formula of [@b22-jer-12-4-333]: VO~2\ peak~ (mL/kg/min)=4.948+0.023×6MWD (m).

Statistical analysis
--------------------

Data were analyzed using Statview software (SAS Institute Inc., Cary, NC, USA) and were expressed as mean values±standard deviations. Wilcoxon signed rank test was done to compare values obtained at the baseline and two months after, and Mann--Whitney test was used to compare baseline characteristics of TB patients and healthy age-matched group. The repeated measures analysis of variance was used to compare the distances recorded at 2, 4, and 6 min during the 6MWT and the Fischer Least Significant Difference *post hoc* test was performed to locate this difference. Pre- and post-6MWT measures were also compared using the Wilcoxon rank test. Interaction between parameters was determined using Spearman correlation test. The level of significance was set at *P*\<0.05.

RESULTS
=======

Twenty-eight smear-positive TB patients newly diagnosed (71% males) and 19 healthy subjects (69% males) were enrolled in the study. At the time of diagnosis (baseline), except age and height, there were significant differences in all anthropometric parameters between TB patients and healthy people. There were also significant differences in baseline cardiorespiratory characteristics between TB patients and healthy people. The performance characteristics were lower in the TB patients compared to healthy group (571.7±121.0 m vs 841.6±53.0 m, *P*\<0.0001 for 6MWD and 18.1±2.8 mL/kg/min vs 24.3±1.2 mL/kg/min, *P*\<0.001 for mean VO~2\ peak~). Baseline characteristics of participants and variations of TB patient's characteristics are presented in [Table 1](#t1-jer-12-4-333){ref-type="table"}.

We recorded significant changes in anthropometric, cardiorespiratory and performance parameters measured in TB patients. Only the BM and the FEV~1~/FEV~6~ ratio did not change over the initial intensive phase of treatment. The rate of anthropometric and performance variations were 4.4% (*P*\<0.01) for weight, 4.5% (*P*\<0.05) for BMI, 2.7% (*P*\<0.05) for MM and 14.8% (*P*\<0.001) for IK, 11.8% (*P*\<0.001) for 6MWD, and 8.8% (*P*\<0.01) for mean VO~2\ peak~.

Concerning the difficulty of the effort, the RPE was higher in TB patients than healthy group (2.9±1.1 vs 1.4±0.3, respectively, *P*\<0.01). But 2 months later, there was a drop of RPE in TB patients from the baseline to the end of the initial intensive phase of treatment (2.9±1.1 vs 2.1±1.1, respectively, *P*\<0.05).

[Table 2](#t2-jer-12-4-333){ref-type="table"} shows the pre- and post-6MWT variations of cardiorespiratory parameters at baseline and 2 months after initiation of treatment. At baseline, there are significant changes in SBP (*P*\<0.05), SpO~2~ (*P*\<0.001), and HR (*P*\<0.0001) after the test. Two months later, we recorded changes in DBP (*P*\<0.001), SpO~2~ (*P*\<0.001), and HR (*P*\<0.0001). The respiratory parameters (FEV~1~, FEV~6~, and FEV~1~/FEV~6~) did not change significantly.

The distances covered by TB every 2 min during the 6MWT are presented in [Fig. 1](#f1-jer-12-4-333){ref-type="fig"}. We noted that neither at diagnosis nor 2 months later, there was no difference between intermediate distances covered each 2 min during each 6MWT. But, significant differences existed between the distance covered at diagnosis and that after 2 months during every 2 min of walk (*P*\<0.0001).

[Fig. 2](#f2-jer-12-4-333){ref-type="fig"} shows interaction between distances covered after 2- and 4-min walking with the total distance covered over the 6 min (6MWD). Strong and significant correlations are registered between the 2-min walk distance (*P*\<0.0001, r=0.95) and 4-min walk distance (*P*\<0.0001, r=0.97) with 6MWD.

DISCUSSION
==========

The baseline characteristics of TB patients are lower than those of a healthy age-matched group of people. However anthropometric, cardiorespiratory and performance parameters of TB patients improved after the initial intensive phase of treatment. This study is the first conducted among TB patients in Cameroon with this aim, and the results can enable the medical doctors to take a better and objective decision during the follow-up and the management of their patients.

The reports on exercise testing and physical functional capacity evaluation in people with chronic respiratory failure as a consequence of TB are very rare, because of the high risk of contamination. [@b24-jer-12-4-333] have already shown that there was a significant difference of physical functional capacity between groups of adult normal persons and patients with TB sequelae. The TB sequelae group had a poor aerobic capacity justifying the great impact of TB sequelae on cardiorespiratory endurance. The results of the present study corroborated with the finding of [@b24-jer-12-4-333] ([Table 1](#t1-jer-12-4-333){ref-type="table"}). Furthermore, the 6MWT has been reported to be important in the objective evaluation in functional exercise capacity in pulmonary rehabilitation ([@b1-jer-12-4-333]). The baseline average 6MWD of TB patients was significantly lower than that of healthy age-matched group (*P*\<0.001). Comparable results were also found in a couple of studies ([@b21-jer-12-4-333]; [@b24-jer-12-4-333]) and demonstrate the high incidence of TB on physical functional capacity of patients.

When comparing the 6MWD of TB patients in the present study with that of TB patients in few previous published studies, we realized that patients in our study had better physical performance. For instance, the baseline average 6MWD in the present study was 571.7±121.0 m, better than that obtained by [@b1-jer-12-4-333] (491.9±57.5 m), [@b4-jer-12-4-333] (342±77 m), [@b11-jer-12-4-333] (525.3±109.0 m), and [@b29-jer-12-4-333] (467±65 m). The differences could be attributed to age, sex or demographic parameters of the studied populations and, suggests the fact that in each context, for a better interpretation of results, specific values of 6MWD should be provided.

The results of the present study showed significant improvement of anthropometric, cardiorespiratory and performance parameters during the initial intensive phase of treatment, except BM and FEV~1~/FEV~6~ ratio. These findings suggest the effectiveness of the proposed treatment. According to respiratory parameters, [@b15-jer-12-4-333] have already obtained that FEV~1~ and forced vital capacity (FVC) changed over time, with both increasing from 0 to 2 months (*P*\<0.001) and 2 to 6 months (*P*\<0.001), when evaluating the impact of pulmonary TB on lung function. Concerning the 6MWD, we noted an improvement of the distance completed after 2 months by 11.8% (*P*\<0.001). This improvement was confirmed the IK (*P*\<0.001), SpO~2~ (*P*\<0.05), FEV~1~ and FEV~6~ (*P*\<0.05), 6MWW (*P*\<0.001), and mean VO~2\ peak~ (*P*\<0.01). The improvement rate of 6MWD was similar to that of [@b15-jer-12-4-333] who obtained a rate of 12.3%, and justify the amelioration of the exercise tolerance of TB patients. [@b29-jer-12-4-333] examined whether exercise training using nontreadmill walking is effective for the improvement of exercise performance of patients with pulmonary TB sequelae and showed that there was no change in pulmonary function (FEV~1~/FVC) but, there was an improvement of VO~2\ peak~ after 2 weeks of daily walking exercise training.

Despite the fact that in the present study, there was no exercise training, the results are in accordance with those of [@b29-jer-12-4-333]. Previous study concluded that it seems not necessary to submit patients suffering from pulmonary TB to pulmonary rehabilitation ([@b12-jer-12-4-333]). Nevertheless, in contrary with our study, there was no SpO~2~ variation after 2 weeks, may be because of the short duration of the exercise training. Exercise training seems not important in the improvement of pulmonary function of TB patients, since the patients of the intervention group in the study of [@b8-jer-12-4-333] did not experience any variation of FEV~1~ and FVC as far as exercise tolerance compared to those of control group.

In the present study, the resting (pre-) cardiorespiratory parameters of the participants were compared with the post-6MWT cardiorespiratory responses ([Table 2](#t2-jer-12-4-333){ref-type="table"}). There were no significant differences in the mean respiratory parameters of the participants following 6MWT compared with the pre-6MWT values. Because of their health status, the walking speed was not sufficient to induce lung function changes during the test. That is the reason why, during the test, the patients were not tired and this finding is in line with that of [@b23-jer-12-4-333], where patients were not tired at the end of the shuttle walking. In the study of [@b29-jer-12-4-333], no pulmonary function variation was also registered in patients with TB sequelae after 2-week exercise training. Furthermore, we recorded significant decrease of SpO~2~ between pre- and posttests (*P*\<0.001). This result is explained by the fact that patients with pulmonary TB sequelae have low oxygen venous pressure as result of oxygen transport limitation ([@b28-jer-12-4-333]). Concerning the blood pressure, the present study showed that SBP changed only at baseline (*P*\<0.05) and the DBP only after 2 months (*P*\<0.01). [@b1-jer-12-4-333] obtained significant variations of SBP and DBP following 6MWT in pulmonary TB patients but the reasons for these changes of pressures were not explained. They concluded that the 6MWT could be useful for the assessment of the cardiovascular parameters of TB patients.

As recommended ([@b5-jer-12-4-333]), we recorded distances at periods 0--2 min, 2--4 min, and 4--6 min, to evaluate the fatigability of TB patients ([Fig. 1](#f1-jer-12-4-333){ref-type="fig"}). The results revealed that there was no significant difference between distances covered in the three periods at baseline and 2 months after. We suggest that TB patients completed the test with a constant speed and without additional fatigue. The 6MWT seems not to be an appropriated test to assess fatigability in TB patients. But in [Fig. 2](#f2-jer-12-4-333){ref-type="fig"}, we found significant correlations between distances covered at 2 min and 6MWD (r=0.95, *P*\<0.0001), and the distance covered at 4 min and 6MWD (r=0.97, *P*\<0.0001). This result supposes that the distance walked at 2 min reflects the 6MWD. Then, we can use the 2-min walk test in the assessment of the exercise tolerance in TB patients. Similar results have already been reported by [@b19-jer-12-4-333] in patients with chronic obstructive pulmonary disease (COPD), who found significant correlations between distance walked in 2 min and 6 min. These authors concluded that the 2-min walk test is valid, practical, simple and well-tolerated for the assessment of exercise capacity in patients with COPD.

In conclusion, this study provides information on the baseline physical functional capacity of TB patients and their recovery during the initial intensive phase of treatment. The 6MWT can detect physical capacity changes among TB patients during the treatment, then, it may be useful in the assessment of physical functional capacity of TB patients. The 2-min walk test is efficient in the assessment of the exercise tolerance in TB patients. The sample size of this study can limit the generalization of the results.
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###### 

Comparison of baseline TB patient's characteristics with healthy group, and variation of TB patient's characteristics

  Characteristic                      TB patients     Healthy subjects                                                  
  ----------------------------------- --------------- ----------------------------------------------------------------- -------------------------------------------------------------------
  Anthropometric                                                                                                        
   Age (yr)                           29±8            \-                                                                28±3
   Height (cm)                        172.0±0.1       \-                                                                173.7±8.7
   Weight (kg)                        59.8±7.9        62.4±7.9[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}           73.7±11.1[\*\*\*](#tfn5-jer-12-4-333){ref-type="table-fn"}
   Body mass index (kg/m^2^)          20.2±2.3        21.1±2.4[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}             24.4±3.0[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}
   Muscle mass (%)                    49.0±6.4        50.3±6.6[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}             67.1±5.1[\*\*\*](#tfn5-jer-12-4-333){ref-type="table-fn"}
   Bone mass (%)                      2.6±0.3         2.6±0.5                                                           3.5±0.3[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}
   Karnosky index (%)                 82.2±7.0        94.4±5.8[\*\*\*](#tfn5-jer-12-4-333){ref-type="table-fn"}         100.0±0[\*\*\*](#tfn5-jer-12-4-333){ref-type="table-fn"}
                                                                                                                        
  Cardiorespiratory and performance                                                                                     
   SBP (mmHg)                         105± 9          118± 11[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}            114± 8[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}
   DBP (mmHg)                         67±9            78± 7[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}              70±5
   SpO~2~ (%)                         96.5±2.5        97.5±1.1[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}             98.2±0.7[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}
   RHR (bpm)                          97±15           88±18[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}              75± 9[\*\*\*](#tfn5-jer-12-4-333){ref-type="table-fn"}
   FEV~1~ (L)                         1.8±0.7         2.1±0.7[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}              3.0±0.8[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}
   FEV~6~ (L)                         1.9±0.8         2.2±0.7[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}              3.4±1.0[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}
   FEV~1~/FEV~6~                      0.95±0.06       0.95±0.10                                                         0.89±0.06[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}
   6MWD (m)                           571.7±121.0     639.0±99.7[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}         841.6±53.0[\*\*\*](#tfn5-jer-12-4-333){ref-type="table-fn"}
   VO~2\ peak~ (mL/kg/min)            18.1±2.8        19.7±2.3[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}             24.3±1.2[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}
   6MWW (kg/m)                        34,441±10,187   40,173.6±9,841.8[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}   61,961.2±9,522.3[\*\*\*](#tfn5-jer-12-4-333){ref-type="table-fn"}
   RPE                                2.9±1.1         2.1±1.1[\*\*](#tfn4-jer-12-4-333){ref-type="table-fn"}            1.4±0.3[\*](#tfn3-jer-12-4-333){ref-type="table-fn"}

Values are presented as mean±standard deviation.

TB, tuberculosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; SpO~2~, oxygen saturation; RHR, resting heart rate; FEV~1~, forced expiratory volume 1 second; FEV~6~, forced expiratory volume 6 seconds; 6MWD, 6-min walk distance; 6MWW, 6-min walk work; VO~2\ peak~, peak oxygen consumption; RPE, rating of perceived exertion.

*P*\<0.05.

*P*\<0.01.

*P*\<0.001.

###### 

Pre- and posttest cardiorespiratory values of tuberculosis patients

  Variable        Baseline    2 Months after                                                          
  --------------- ----------- ----------------------------------------------------------- ----------- ---------------------------------------------------------
  SBP             105±9       110±12[\*](#tfn7-jer-12-4-333){ref-type="table-fn"}         118±11      120±10
                                                                                                      
  DBP             67±9        69±10                                                       78±7        83± 11[\*\*](#tfn8-jer-12-4-333){ref-type="table-fn"}
                                                                                                      
  SpO~2~          96.5±2.5    93.3±4.7[\*\*\*](#tfn9-jer-12-4-333){ref-type="table-fn"}   97.5±1.1    95.2±3.8[\*\*](#tfn8-jer-12-4-333){ref-type="table-fn"}
                                                                                                      
  HR              97±15       147±19[\*\*\*](#tfn9-jer-12-4-333){ref-type="table-fn"}     88±18       150±21[\*\*\*](#tfn9-jer-12-4-333){ref-type="table-fn"}
                                                                                                      
  FEV~1~          1.8±0.7     1.7±0.7                                                     2.1±0.7     2.1±0.8
                                                                                                      
  FEV~6~          1.9±0.8     1.8±0.8                                                     2.2±0.7     2.2±0.8
                                                                                                      
  FEV~1~/FEV~6~   0.95±0.06   0.93±0.10                                                   0.95±0.10   0.96±0.05

6MWT, 6-min walk test; SBP, systolic blood pressure; DBP, diastolic blood pressure; SpO~2~, oxygen saturation; HR, heart rate; FEV~1~, forced expiratory volume 1 second; FEV~6~, forced expiratory volume 6 second.

*P*\<0.05.

*P*\<0.01.

*P*\<0.001.
